Overview: Beta-HCG Tumor Marker TestIntroduction: The Beta-HCG Tumor Marker Test measures beta HCG as a tumor marker to diagnose cancers like testicular cancer, causing lumps or pain. Aligned with 2023 ASCO guidelines, it uses an immunoassay for high sensitivity, aiding in cancer screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in immunology for patients with suspected malignancies, such as germ cell tumors.
Other Names: HCG Beta Tumor Assay, Tumor Marker HCG Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: HCG as a tumor marker was identified in the 1970s. Immunoassays improved in the 1980s, enhancing accuracy for cancer diagnosis.
Purpose: Diagnoses cancers (e.g., testicular, ovarian), guides treatment, and monitors beta HCG levels in patients with lumps or pain.
Test Parameters: 1. Beta HCG (Tumor Marker)
Pretest Condition: No fasting required. Collect serum or plasma at any time. Report symptoms like lumps or pain, and list medications.
Specimen: 2-5 mL serum (SST) or 2-4 mL plasma (EDTA). Centrifuge within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document lumps, pain, or history of cancer. Include current medications, especially chemotherapeutics, and family history.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for cancer treatment.
Procedural Considerations: Uses an immunoassay to measure beta HCG as a tumor marker. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Hemolysis, improper storage, or medications (e.g., HCG-containing drugs) can affect results. Pregnancy may cause false positives.
Clinical Significance: Elevated beta HCG levels suggest cancers (e.g., testicular cancer), prompting further evaluation or treatment. Normal levels may require additional testing.
Specialist Consultation: Consult an oncologist for result interpretation and cancer management planning.
Additional Supporting Tests: AFP, LDH, or tumor imaging to confirm cancer diagnosis and stage.
Test Limitations: Pregnancy or non-malignant conditions may elevate HCG. Clinical correlation is needed.
References: ASCO Tumor Marker Guidelines, 2023; Journal of Clinical Oncology, Gilligan TD, 2022.
